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More patent protection 
for medicines with a 
new purpose
You are right to urge the US 
government and others to 
encourage the re-use of old 
medicines by granting exclusivity 
rights (Editorial, Nature 465, 267; 
2010). But it is not correct to say 
that the European Union (EU) 
already rewards innovators in this 
area with a further year of patent 
protection.
The EU awards an extra year’s 
exclusivity for the technical 
data that are used to obtain the 
marketing authorization for the 
product, as long as the indications 
constitute a “significant clinical 
benefit”. Because data exclusivity 
usually expires before patent 
protection, this provision is of 
limited value. 
One solution would be for 
regulators to extend patent life 
when existing medicines have 
been repurposed for new uses 
— but this would only assist 
projects undertaken by the original 
patentee. 
Another would be to exclude 
generic products from the market 
for a limited period should a third 
party, or the patentee, repurpose 
a medicine. The repurposed use 
could be assessed according to 
similar criteria and judged against 
new indications of significant 
clinical benefit (where these do 
not amount to repurposing). 
However, this would still not 
protect companies in situations 
in which generic products are 
Closure threat to  
key museum  
research facility
As leading representatives of the 
environmental and Earth science 
communities, we are gravely 
concerned about the proposed 
closure of the micropalaeontology 
research group at London’s 
Natural History Museum (see 
go.nature.com/KCppCe). 
Micropalaeontology is of 
considerable strategic and 
international importance. 
It underpins biological 
and geochemical proxy 
reconstructions of past climates. 
It is critical for industrial oil and 
gas exploration. It allows the 
evolutionary and palaeobiological 
study of organisms that have the 
most complete fossil record. The 
museum’s micropalaeontology 
research group has made 
acclaimed contributions in all of 
these areas. 
Loss of this expertise will 
compromise research in these 
fields and the training of the 
next generation of industry and 
research micropalaeontologists.
We accept that the Natural 
History Museum’s researchers 
are not directly responsible 
for collections management. 
But micropalaeontologists are 
needed to interface with the 
many professional users of 
the museum’s resources. The 
use and development of its 
micropalaeontology collection is 
likely to suffer in the long term as 
a result of the research group’s 
closure. 
The museum’s trustees and 
director are being forced to 
respond to funding constraints 
that will require savings to be 
Gender agenda: let’s 
track women’s trial 
participation
Your discussion of sex bias in 
biomedical research (Nature 
465, 665 and 688–690; 2010) 
doesn’t mention the poor basic 
monitoring of female participation 
in clinical trials. Only the Office of 
Research on Women’s Health in 
the United States systematically 
collects and publishes such data, 
and its statistics relate solely to 
publicly funded research. 
The research community needs 
to be able to access participation 
data easily so that nuanced 
analysis of inclusion patterns can 
be conducted — for example, to 
take account of the proportion 
of women in non-sex-specific 
research. A simple solution would 
be for clinical-trials registries 
to collect data on the sex of 
participants.
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made across all departments. 
Instead of closing a whole 
research group with such key 
expertise, we urge the museum’s 
management to produce a more 
balanced set of proposals that will 
be less damaging to palaeoclimate 
research, industrial biostratigraphy 
and evolutionary palaeobiology 
(see also go.nature.com/Eo4Thh).
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Coordinated action 
needed for Europe’s 
research programmes 
Plans are under way for integrated 
European research infrastructures 
that will foster synergy and 
collaboration among Europe’s 
scientists (see go.nature.
com/fsnB7a). The European 
Strategy Forum on Research 
Infrastructures (ESFRI) has put 
forward more than 40 priority 
projects, but these will be hard 
to implement without extensive 
European cooperation, even on a 
realistic timescale of 10–15 years. 
Construction and running 
costs must be financed by 
national mechanisms, which 
will be difficult if every project 
applies to all 37 ESFRI member 
states and requires a separate 
national decision, as is now 
planned. Without coordinated 
action between the ESFRI 
member states and the European 
Commission, this process will be 
chaotic, inconsistent, costly and 
time-consuming.
A European decision-
taking body of member-state 
representatives could be set 
up that would implement 
agreed member-state policy 
on prioritization, funding, site 
selection and construction of 
the projects, while ensuring that 
legitimate national interests are 
taken into account. European 
countries could, for example, 
act together to equip the ESFRI 
with the extra responsibilities 
necessary to realize its plans.
Integration of existing expertise 
into the planning of the ESFRI 
projects could be improved. As 
well as developing appropriate 
legal and governance systems, the 
new research infrastructures will 
have to mobilize, recruit and train 
specialist staff to operate them.
Several European institutions 
have already solved these 
problems. The intergovernmental 
EIROforum organizations 
that operate some of Europe’s 
existing international research 
infrastructures have governance 
designed for international 
membership and operation, 
and sustainable, performance-
based funding systems. These 
should serve as models for the 
new research infrastructures 
and as sources of expert advice 
(see Establishing New Research 
Infrastructures in Europe — The 
EIROforum Experience; available at 
go.nature.com/4JfVEj).
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already on the market. 
Also, holders of repurpose 
patents could be allowed to 
enforce the patent when generic 
off-label use is damaging their 
monopoly. 
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